Low-grade Lymphoproliferative Disorders (CLL, HCL, T-PLL) – Adult

PATIENT PRESENTATION

- Untreated – all stages with therapy indication
- Prior therapy

TREATMENT

- Standard of care:
  - Young/fit GVH – mutated
    - Fludarabine, cyclophosphamide and rituximab (FCR)
  - Young/fit IGVH – unmutated
    - Ibrutinib
  - Elderly/comorbidities
    - Ibrutinib
    - Chlorambucil and obinutuzumab
  - Del(17p) (any age)
    - Ibrutinib

- Relapsed/refractory non-del(17p):
  - Ibrutinib
  - Venetoclax and rituximab
  - Idelalisib and rituximab

- Del(17p):
  - Venetoclax (with or without rituximab)
  - Ibrutinib

- Hairy cell leukemia:
  - Phase II clinical trial of cladribine and rituximab

- Relapsed:
  - Cladribine or pentostatin plus rituximab
  - Vemurafenib and rituximab
  - Moxetumomab pasudotox-tdfk and rituximab

- T-cell prolymphocytic leukemia:
  - Alemtuzumab

SURVEILLANCE

- Surveillance as per treatment plan

CLL = chronic lymphocytic leukemia
HCL = hairy cell leukemia
T-PLL = t-cell prolymphocytic leukemia
IGVH = immunoglobulin heavy-chain variable-region

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

Note: Consider Clinical Trials as treatment options for eligible patients. Leukemia patients should be referred and treated at a comprehensive cancer center.

Greater than or equal to 18 years old

1 See Physical Activity, Nutrition, and Tobacco Cessation algorithms; ongoing reassessment of lifestyle risks should be a part of routine clinical practice

Leukemia Newsletter: http://www.mdanderson.org/leukemia

Copyright 2019 The University of Texas MD Anderson Cancer Center

Department of Clinical Effectiveness V6
Approved by The Executive Committee of the Medical Staff 02/26/2019
Low-grade Lymphoproliferative Disorders (CLL, HCL, T-PLL) – Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

SUGGESTED READINGS


Low-grade Lymphoproliferative Disorders (CLL, HCL, T-PLL) – Adult

Disclaimer: This algorithm has been developed for MD Anderson using a multidisciplinary approach considering circumstances particular to MD Anderson’s specific patient population, services and structure, and clinical information. This is not intended to replace the independent medical or professional judgment of physicians or other health care providers in the context of individual clinical circumstances to determine a patient’s care. This algorithm should not be used to treat pregnant women.

DEVELOPMENT CREDITS

This practice algorithm is based on majority expert opinion of the Leukemia Center Faculty workgroup at the University of Texas MD Anderson Cancer Center. It was developed using a multidisciplinary approach that included input from the following:

- Yesid Alvarado, MD (Leukemia)
- Michael Andreeff, PhD, MD (Leukemia)
- Christopher Benton, MD (Leukemia)
- Kapil Bhatta, MD (Leukemia)
- Gautam Borthakur, MBBS (Leukemia)
- Prithviraj Bose, MD (Leukemia)
- Jan Burger, MD (Leukemia)
- Jorge Cortes, MD (Leukemia)
- Naval Daver, MD (Leukemia)
- Courtney DiNardo, MD (Leukemia)
- Zeev Estrov, MD (Leukemia)
- Alessandra Ferrajoli, MD (Leukemia)
- Emil Freireich, MD (Leukemia)
- Wendy Garcia, BS*
- Guillermo Garcia-Manero, MD (Leukemia)
- Ghayas Issa, MD (Leukemia)
- Elias Jabbour, MD (Leukemia)
- Nitin Jain, MBBS (Leukemia)
- Tapan Kadia, MD (Leukemia)
- Hagop M. Kantarjian, MD (Leukemia)†
- Michael Keating, MD (Leukemia)
- Marina Konopleva, MD (Leukemia)
- Steven Kornblau, MD (Leukemia)
- Lucia Masarova, MD (Leukemia)
- Guillermo Montalban-Bravo, MD (Leukemia)
- Kiran Naqvi, MD (Leukemia)
- Maro Ohanian, DO (Leukemia)
- Naveen Pemmaraju, MD (Leukemia)
- Farhad Ravandi-Kashani, MD (Leukemia)
- Michael Ryting, MD (Pediatrics)
- Koji Sasaki, MD (Leukemia)
- Nicholas Short, MD (Leukemia)
- Koichi Takahashi, MD (Leukemia)
- Philip Thompson, MBBS (Leukemia)
- Srdan Verstovsek, MD (Leukemia)
- Sonal Yang, PharmD*
- Musa Yilmaz, MD (Leukemia)

† Core Development Leads
* Clinical Effectiveness Development Team